Vol 24, No 6 (2017)
Original articles — Clinical cardiology
Published online: 2017-06-20

open access

Page views 1599
Article views/downloads 1558
Get Citation

Connect on Social Media

Connect on Social Media

Link of renal microcirculatory dysfunction to increased coronary microcirculatory resistance in hypertensive patients

Cong Lin, Pu Zhang, Yangjing Xue, Yinqing Huang, Kangting Ji
Pubmed: 28653312
Cardiol J 2017;24(6):623-632.


Background: This study investigated the correlation between renal microcirculation and coronary microcirculation in hypertensive patients. Methods: Participants consisted of 231 consecutive candidates who were referred to the Second Affiliated Hospital of Wenzhou Medical University from March 2014 to May 2016 for elective coronary angiography due to suspected myocardial ischemia. All participants were evaluated for the index of microvascular resistance (IMR), coronary flow reserve (CFR), and fractional flow reserve (FFR) us¬ing a pressure wire. Blood and urine samples were collected for determination of the levels of urinary microalbuminuria (mALB), b2-microglobulin (b2-MG), serum cystatin C (CysC), and uric acid (UA). All participants were categorized into two groups according to the renal microcirculatory function. Results: Participants in the observation group had a higher IMR (31 ± 5 vs. 22 ± 6; p < 0.01) and a lower FFR (0.84 ± 0.10 vs. 0.87 ± 0.09 U; p < 0.05) during hyperemia than those in the control group. Linear regression tests revealed that mALB, b2-MG, CysC, and UA levels were positively cor¬related with IMR (r = 0.610, 0.553, 0.701, and 0.647, respectively, p < 0.01). The hs-CRP levels were positively correlated with IMR (r = 0.419, p < 0.01). Multiple regression analysis indicated that renal microcirculation was an independent predictor of IMR. Conclusions: Renal microcirculatory dysfunction in hypertensive patients is characterized by higher IMR and lower FFR; in addition, it is closely correlated with an increased coronary microcirculatory resistance.

Article available in PDF format

View PDF Download PDF file


  1. Heagerty AM, Aalkjaer C, Bund SJ, et al. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension. 1993; 21(4): 391–397.
  2. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010; 12(6): 448–455.
  3. Bidani AK, Polichnowski AJ, Loutzenhiser R, et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013; 22(1): 1–9.
  4. Gowda S, Desai PB, Kulkarni SS, et al. Markers of renal function tests. N Am J Med Sci. 2010; 2(4): 170–173.
  5. Ng MKC, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006; 113(17): 2054–2061.
  6. Fearon W, Kobayashi Y. Invasive Assessment of the Coronary Microcirculation. JACC: Cardiovasc Interv. 2016; 9(8): 802–804.
  7. Yong ASC, Ho M, Shah MG, et al. Coronary microcirculatory resistance is independent of epicardial stenosis. Circ Cardiovasc Interv. 2012; 5(1): 103–108, S101–S102.
  8. Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003; 107(25): 3129–3132.
  9. Melikian N, Vercauteren S, Fearon WF, et al. Quantitative assessment of coronary microvascular function in patients with and without epicardial atherosclerosis. EuroIntervention. 2010; 5(8): 939–945.
  10. Layland J, MacIsaac AI, Burns AT, et al. When collateral supply is accounted for epicardial stenosis does not increase microvascular resistance. Circ Cardiovasc Interv. 2012; 5(1): 97–102.
  11. Aarnoudse W, Fearon WF, Manoharan G, et al. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation. 2004; 110(15): 2137–2142.
  12. Ng MKC, Yong ASC, Ho M, et al. The index of microcirculatory resistance predicts myocardial infarction related to percutaneous coronary intervention. Circ Cardiovasc Interv. 2012; 5(4): 515–522.
  13. Fearon WF, Low AF, Yong AC, et al. Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 2013; 127(24): 2436–2441.
  14. Yoo SH, Yoo TK, Lim HS, et al. Index of microcirculatory resistance as predictor for microvascular functional recovery in patients with anterior myocardial infarction. J Korean Med Sci. 2012; 27(9): 1044–1050.
  15. Kobayashi Y, Fearon WF. Invasive coronary microcirculation assessment--current status of index of microcirculatory resistance. Circ J. 2014; 78(5): 1021–1028.
  16. Wu Z, Ye F, You W, et al. Microcirculatory significance of periprocedural myocardial necrosis after percutaneous coronary intervention assessed by the index of microcirculatory resistance. Int J Cardiovasc Imaging. 2014; 30(6): 995–1002.
  17. Lanza GA, Buffon A, Sestito A, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol. 2008; 51(4): 466–472.
  18. Miyazaki T, Ashikaga T, Ohigashi H, et al. Impact of smoking on coronary microcirculatory resistance in patients with coronary artery disease. Int Heart J. 2015; 56(1): 29–36.
  19. Leung M, Leung DY. Coronary microvascular function in patients with type 2 diabetes mellitus. EuroIntervention. 2016; 11(10): 1111–1117.
  20. Tonino PAL, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010; 55(25): 2816–2821.
  21. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3): 213–224.
  22. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13): 1296–1305.
  23. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001; 12(2): 218–225.
  24. Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001; 38(3): 705–711.
  25. Chade AR, Brosh D, Higano ST, et al. Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. Kidney Int. 2006; 69(2): 266–271.
  26. Granata A, Fiorini F, Andrulli S, et al. Doppler ultrasound and renal artery stenosis: An overview. J Ultrasound. 2009; 12(4): 133–143.
  27. Zucchelli PC. Hypertension and atherosclerotic renal artery stenosis: diagnostic approach. J Am Soc Nephrol. 2002; 13 (Suppl 3): S184–S186.
  28. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens. 2001; 19(7): 1209–1215.
  29. Mancia G, Backer GDe, Dominiczak A, et al. 007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6): 1105–1187.
  30. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42(5): 1050–1065.
  31. Nakanishi K, Fukuda S, Shimada K, et al. Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. Circ J. 2012; 76(8): 1958–1964.
  32. Shah NR, Charytan DM, Murthy VL, et al. Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD. J Am Soc Nephrol. 2016; 27(6): 1823–1829.
  33. Lerman A, Holmes DR, Herrmann J, et al. Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? Eur Heart J. 2007; 28(7): 788–797.
  34. Tsioufis C, Tsiachris D, Kasiakogias A, et al. Preclinical cardiorenal interrelationships in essential hypertension. Cardiorenal Med. 2013; 3(1): 38–47.
  35. Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000; 35(4): 898–903.
  36. Hoke M, Amighi J, Mlekusch W, et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke. 2010; 41(4): 674–679.
  37. Bielecka-Dabrowa A, Gluba-Brzózka A, Michalska-Kasiczak M, et al. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci. 2015; 16(5): 10715–10733.
  38. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007; 115(2): 173–179.
  39. Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004; 110(16): 2342–2348.
  40. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134(8): 629–636.
  41. Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001; 19(6): 1149–1159.
  42. Moody WE, Edwards NC, Madhani M, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis. 2012; 223(1): 86–94.
  43. Guan Z, VanBeusecum JP, Inscho EW. Endothelin and the renal microcirculation. Semin Nephrol. 2015; 35(2): 145–155.
  44. Fukuta H, Ohte N, Mukai S, et al. Relationship between renal function, aortic stiffness and left ventricular function in patients with coronary artery disease. Circ J. 2009; 73(9): 1740–1745.
  45. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005; 96(7): 946–951.
  46. Guijarro C. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 104(22): E127.
  47. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18): 2165–2168.
  48. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol. 2001; 38(7): 1850–1858.
  49. Li JJ, Qin XW, Li ZC, et al. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta. 2007; 385(1-2): 43–47.
  50. Enli Y, Turk M, Akbay R, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther. 2008; 25(1): 37–44.